Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on March 3, 2026 to three new employees under its Amended and Restated 2014 Inducement Plan as permitted by Nasdaq Listing Rule 5635(c)(4).

One hire received options for 2,400 shares (10-year term, $22.10 exercise price, four-year vesting). Three hires received 5,500 RSUs vesting annually over four years beginning March 1, 2027.

News Market Reaction – PCRX

-3.76%

1 alert

-3.76% News Effect

On the day this news was published, PCRX declined 3.76%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement stock options: 2,400 shares Inducement RSUs: 5,500 shares Option term: 10 years +5 more

8 metrics

Inducement stock options 2,400 shares Granted to one new employee under 2014 Inducement Plan

Inducement RSUs 5,500 shares Aggregate RSUs granted to three new employees

Option term 10 years Term of inducement stock options granted March 3, 2026

Vesting period 4 years Equity awards vest over four-year schedules

Initial cliff vesting 25 percent Options vest 25% on first anniversary of employment start date

Subsequent vesting period 36 months Remaining option shares vest in equal quarterly installments

Exercise price $22.10 per share Closing price on Nasdaq Global Select Market on grant date

RSU vesting schedule 4 annual installments RSUs vest annually starting March 1, 2027

Market Reality Check

Price: $22.44 Vol: Volume 931,056 is slightl...

normal vol

$22.44 Last Close

Volume Volume 931,056 is slightly above the 20-day average of 893,715, suggesting typical trading interest ahead of this HR-related update. normal

Technical Shares at $22.91 are trading below the 200-day MA of $23.86, indicating a pre-existing downward/sideways bias before this inducement grant news.

Peers on Argus

Peers showed mixed moves, with AMPH up 3.91%, COLL down 4.67%, and HROW down 7.3...

Peers showed mixed moves, with AMPH up 3.91%, COLL down 4.67%, and HROW down 7.35%, while PCRX was unchanged; this points to stock-specific rather than sector-driven dynamics.

Historical Context

5 past events · Latest: Mar 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Conference participation	Neutral	+3.4%	Announcement of a Barclays healthcare conference fireside chat and webcast access.
Mar 02	Clinical registry data	Positive	-2.9%	IGOR real-world data showing benefits for EXPAREL and iovera° in knee pain.
Feb 26	Earnings results	Positive	-3.0%	Q4 and full-year 2025 results with revenue growth and positive net income.
Feb 12	Earnings date notice	Neutral	+1.5%	Scheduling announcement for release of 2025 financial results and conference call.
Feb 12	Policy survey results	Positive	-1.3%	NOPAIN Act survey highlighting increased non-opioid use and reduced opioid prescribing.

Pattern Detected

Recent history shows several instances where positive fundamental or clinical news (IGOR data, earnings, policy survey) were followed by negative price reactions, while neutral event announcements often saw modest gains.

Recent Company History

Over the past month, Pacira has reported multiple developments, including a Feb 26 earnings release with $196.9M Q4 and $726.4M 2025 revenue, which saw a -3.01% next-day move. Positive IGOR real‑world data on Mar 2 was followed by a -2.88% reaction, while a neutral fireside chat announcement on Mar 4 coincided with a +3.44% move. Earlier in February, an earnings date notice and NOPAIN Act survey news produced smaller mixed reactions. Today’s routine inducement grants fit into an ongoing cadence of operational and governance updates.

Market Pulse Summary

This announcement details routine inducement equity awards—2,400 stock options and 5,500 RSUs—grante...

Analysis

This announcement details routine inducement equity awards—2,400 stock options and 5,500 RSUs—granted under Nasdaq Listing Rule 5635(c)(4) to new hires, with four-year vesting and an exercise price of $22.10. Against a backdrop of recent earnings and clinical updates, it mainly signals ongoing hiring and alignment of employee incentives with shareholders. Investors can monitor future filings, additional equity awards, and subsequent earnings or clinical milestones to gauge how compensation structures evolve alongside business performance.

Key Terms

nasdaq listing rule 5635(c)(4), inducement plan, stock options, restricted stock units, +2 more

6 terms

nasdaq listing rule 5635(c)(4) regulatory

"In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”)"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

stock options financial

"One employee received stock options to purchase an aggregate of 2,400 shares..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

restricted stock units financial

"three employees received restricted stock units for an aggregate of 5,500 shares..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting schedule financial

"The stock options have a 10-year term and a four-year vesting schedule..."

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

exercise price financial

"The stock options have an exercise price of $22.10 per share..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

One employee received stock options to purchase an aggregate of 2,400 shares of Pacira common stock and three employees received restricted stock units for an aggregate of 5,500 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $22.10 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on March 1, 2027.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com

Media Contact:
Sara Marino, (973) 370-5430
sara.marino@pacira.com

FAQ

What inducement awards did Pacira (PCRX) grant on March 3, 2026?

Pacira granted stock options for 2,400 shares and RSUs for 5,500 shares to three new employees. According to Pacira, the options have a 10-year term and RSUs vest annually over four years starting March 1, 2027.

What are the exercise price and vesting terms for the PCRX stock options?

The options have an exercise price of $22.10 and a four-year vesting schedule. According to Pacira, 25% vests after one year, then equal quarterly installments over the following 36 months; options expire after ten years.

Why were the Pacira (PCRX) inducement awards approved without stockholder approval?

The People & Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4) as material inducements to hire new employees. According to Pacira, the grants were made under its Amended and Restated 2014 Inducement Plan.

When do the restricted stock units (RSUs) granted by Pacira (PCRX) begin vesting?

The RSUs vest annually in four equal installments beginning on March 1, 2027. According to Pacira, each restricted stock unit represents the contingent right to receive one share and is subject to continued employment.

How many employees received inducement awards and what types were they in the PCRX grant?

Three new employees received inducement awards: one received stock options and three received RSUs totaling 5,500 shares. According to Pacira, the awards were granted March 3, 2026 under the Inducement Plan.